Royal Bank of Canada is a leading financial services institution that provides a wide range of banking and financial solutions to individuals, businesses, and institutions. The bank offers personal and commercial banking services, wealth management, investment banking, and capital markets services. With a robust network of branch locations and digital platforms, it aims to meet the diverse needs of its clients while focusing on innovation and customer service. Royal Bank of Canada is committed to enhancing the financial well-being of its customers and leveraging its expertise to support economic growth in the communities it serves. Read More
What Happened? Shares of work management platform Asana (NYSE:ASAN) jumped 12.7% in the afternoon session after the company reported an impressive “beat and ...
What Happened? Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 3.8% in the afternoon session after the company announced tha...
Royal Bank Of Canada (NYSE:RY) reported fiscal second-quarter earnings of CAD 5.5 billion, with adjusted earnings of CAD 5.6 billion, as management highlighted strong results across capital markets, wealth management and Canadian banking businesses.
President and Chief Executive Officer Dave McKay
As FactSet Research Systems has notably lagged the broader market over the past 52 weeks, Wall Street analysts maintain a cautious outlook about the stock’s prospects.
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio.
Speaking at RBC Capital Markets’ 20
Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while preparing to share additional data from its IRF5 program later this year.
Speaking at an RBC Capital Mar
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets’ 2026
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch
Despite Air Products and Chemicals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams.
Berger said Gilead is focused on advancing Trodel
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets.
Peters said Exelixis’ guidance
Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capi
Cboe Global Markets has considerably outperformed the broader market over the past 52 weeks, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.
